Enter your keywords
HOME
About Us
NEWSLETTER
To search AlzGene, use the "Keyword" search on the
AlzGene search page
.
NEWS
All News
Conference Coverage
Series
WEBINARS
All Webinars
Databases
AlzBiomarker
AlzPedia
AlzRisk
Antibodies
Genetics
AlzGene
HEX
Mutations
Protocols
Research Models
Therapeutics
PAPERS
All Papers
Papers of the Week
Milestone
Alzforum Recommends
PROFESSIONAL RESOURCES
Conference Calendar
Grants
Jobs
Member Directory
ABOUT AD
AD Overview
Early-Onset Familial
The HBO Alzheimer's Project
Supported Browsers
MY ALZFORUM
My AlzForum Home
View Library
View Notifications
Set Notifications
Edit Profile
AlzGene - Gene overview of all published AD-association studies for ACE
Gene:
ACE
(DCP; DCP1; CD143; MGC26566; ACE1)
View on ALSGene
View on MSGene
View on PDGene
View on SZGene
Protein:
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
Chromosome:
17
(View:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
MT
)
Status:
Updated 18 April 2011
1. Case-Control Studies (by ethnic group)
AD Cases
Normal Controls
Study
Population
Source
# Polys
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Alvarez, 1999
Spain
CL
1
(detail)
350
(56%)
C
-
72 + 9
(-)
517
(-)
-
Positive
Blomqvist, 2005
Overlaps with
Kehoe, 2003
CL
7
(detail)
-
-
-
-
-
-
n.a.
Blomqvist, 2005
Overlaps with
Kehoe, 2003
CL
7
(detail)
-
-
-
-
-
-
n.a.
Bruandet, 2008
France
CO
2
(detail)
141
(60%)
C
-
78.7 + 5.8
(-)
6467
(61%)
73.8 + 5.3
(-)
Negative
Buss, 2002
Europe (mixed)
CL
1
(detail)
261
(75%)
C
-
75.5 + 8.8
(-)
306
(60%)
67.9 + 12.5
(-)
Negative
Carbonell, 2003
UK
CL
1
(detail)
80
(-)
C
-
79
(-)
65
(-)
75
(-)
Negative
Chalmers, 2004
Overlaps with
Kehoe, 2003
CL
1
(detail)
-
-
-
-
-
-
n.a.
Chapman, 1998
Israel
CL
1
(detail)
49
(-)
C
74.8 + 9.7
(-)
-
40
(-)
72.7 + 7.8
(-)
Negative
Corder, 2006
Overlaps with
Lehmann, 2005
CL
1
(detail)
315
(-)
M
-
-
260
(-)
-
n.a.
Corder, 2008
Overlaps with
Kehoe, 2003
CL
6
(detail)
938
(-)
U
-
-
397
(-)
-
n.a.
Corneveaux, 2010
USA, UK & Netherlands (TGEN)
CL
1
(detail)
1019
(64%)
N
-
-
591
(48%)
-
n.a.
Cousin, 2009
France
CL
2
(detail)
428
(-)
C
64.9 + 9.9
(-)
-
475
(-)
66.2 + 10.8
(-)
Negative
Edwards, 2009
USA
CL
8
(detail)
296
(-)
M
71.7 + 7.8
(-)
79 + 6.6
(-)
566
(-)
73.6 + 6.3
(-)
Positive
Farrer, 2000
USA, Canada & Italy
CL
1
(detail)
236
(-)
U
75.2 + 7.6
(52-94)
-
169
(-)
70.2 + 10.2
(38-96)
Trend
Farrer, 2000
Russia
CL
1
(detail)
150
(-)
U
64.6 + 8.8
(40-88)
-
206
(-)
64.9 + 11.4
(40-91)
Trend
Feulner, 2009
Germany
CL
14
(detail)
491
(57%)
C
-
72.2
(-)
479
(46%)
39.5
(-)
Negative
Ghebranious, 2010
USA (PMRP)
PO
4
(detail)
153
(60%)
C
-
78.2 + 6.4
(-)
302
(66%)
87.2 + 3
(-)
Positive
Giedraitis, 2009
Sweden (ULSAM)
CL
9
(detail)
86
(0%)
C
80.2
(72-85)
-
404
(0%)
81.8
(80-84)
Negative
Helbecque, 2009
Overlaps with
Richard, 2001
CL
3
(detail)
376
(64%)
C
-
75 + 5
(-)
444
(64%)
74 + 8
(-)
Positive
Isbir, 2000
Turkey
CL
1
(detail)
35
(74%)
C
-
73.9 + 7.4
(-)
29
(31%)
73.6 + 13.6
(-)
Trend
Isbir, 2001
Same as Isbir, 2000
CL
1
(detail)
-
-
-
-
-
-
n.a.
Katzov, 2004
Overlaps with
Kehoe, 2003
CL
3
(detail)
-
-
-
-
-
-
n.a.
Kehoe, 1999
Ireland
CL
1
(detail)
209
(-)
U
76.6 + 6.4
(-)
-
198
(-)
77.1 + 6.4
(-)
Positive
Kehoe, 1999
UK (London)
CL
1
(detail)
135
(-)
U
82.3 + 6.7
(-)
-
111
(-)
80.8 + 4.5
(-)
Positive
Kehoe, 1999
UK (Cardiff)
CL
1
(detail)
198
(-)
U
70.3 + 9.4
(-)
-
77
(-)
73.5 + 6.2
(-)
Positive
Kehoe, 2003
Sweden (Set A)
CL
7
(detail)
204
(61%)
M
71.8 + 8.6
(-)
77.5 + 8.2
(-)
185
(58%)
73.4 + 9.6
(-)
Positive
Kehoe, 2003
Scotland (Set B)
CL
7
(detail)
121
(58%)
M
52.4 + 6.8
(-)
57.8 + 6.3
(-)
152
(38%)
58.2 + 9.8
(-)
Positive
Kehoe, 2003
Sweden (Set C)
CL
3
(detail)
186
(52%)
M
72.8 + 7.6
(-)
76.2 + 6.8
(-)
326
(66%)
83.6 + 3.2
(-)
Positive
Kehoe, 2003
UK (Set D)
CL
4
(detail)
335
(60%)
M
72.9 + 9.2
(-)
80.7 + 8
(-)
110
(46%)
77.1 + 9.1
(-)
Positive
Koelsch, 2005
Germany
CL
1
(detail)
351
(68%)
C
-
72.9 + 9.1
(-)
348
(53%)
72.5 + 7.3
(-)
Positive
Lehmann, 2005
UK
CL
1
(detail)
203
(57%)
M
70.5 + 9.1
(-)
-
248
(52%)
76.1 + 9.2
(-)
Negative
Lendon, 2002
UK
CL
1
(detail)
214
(54%)
N
61.3 + 9.2
(40-84)
-
99
(-)
-
Negative
Li, 2008
Canada
CL
3
(detail)
753
(58%)
C
71.9 + 8.5
(-)
77.8 + 8.6
(-)
736
(64%)
73.4 + 7.9
(-)
Trend
Mattila, 2000
Finland
CL
1
(detail)
80
(64%)
M
-
-
67
(45%)
75.9 + 7.3
(-)
Positive
Miners, 2009
Overlaps with
Kehoe, 2003
CL
4
(detail)
101
(59%)
M
-
79.3 + 9.6
(-)
51
(65%)
77.7 + 10.8
(-)
n.a.
Monastero, 2002
Italy
CL
1
(detail)
149
(65%)
C
69.7 + 7.7
(50-85)
72 + 9.7
(51-89)
149
(-)
73.3 + 7.6
(-)
Negative
Myllykangas, 2000
Finland
PO
1
(detail)
121
(87%)
N
-
92.2 + 3.1
(-)
75
(83%)
92.3 + 3.8
(-)
Negative
Nacmias, 2006
Italy
CL
1
(detail)
388
(61%)
C
68.5 + 7
(-)
-
303
(65%)
90.9 + 12.5
(-)
Negative
Narain, 2000
UK
CL
1
(detail)
239
(64%)
N
-
81.2 + 7.8
(-)
342
(59%)
82.1 + 3.8
(-)
Positive
Palumbo, 1999
Italy
CL
1
(detail)
140
(63%)
C
70.4 + 5.9
(-)
74.3 + 6.2
(-)
40
(70%)
71 + 4
(-)
Negative
Panza, 2002
Italy
CL
1
(detail)
141
(-)
U
-
-
268
(-)
-
Negative
Panza, 2003
Same as Panza, 2002
CL
1
(detail)
-
-
-
-
-
-
n.a.
Prince, 2001
Sweden
CL
1
(detail)
204
(61%)
M
-
-
186
(58%)
-
Negative
Reiman, 2007
Overlaps with
Corneveaux, 2010
CL
3
(detail)
861
(-)
M
-
74.9 + 6.6
(-)
550
(-)
77.4 + 7.3
(-)
Negative
Richard, 2001
France (I)
CL
1
(detail)
433
(64%)
C
73 + 5
(-)
75 + 6
(-)
475
(66%)
75 + 8
(-)
Positive
Richard, 2001
France (II)
CL
1
(detail)
56
(-)
C
-
85 + 6
(-)
221
(76%)
-
Positive
Sarajarvi, 2010
Finland
CL
1
(detail)
642
(68%)
C
71 + 7
(43-89)
-
682
(60%)
69 + 6
(37-87)
Negative
Scacchi, 1998
Italy
CL
1
(detail)
80
(71%)
C
-
83.5 + 5.9
(-)
155
(77%)
78.3 + 7
(-)
Negative
Seripa, 2003
Italy
CL
1
(detail)
126
(59%)
C
7.2
(-)
69.3 + 7
(53-84)
106
(50%)
62.4 + 10.5
(42-86)
Negative
Seripa, 2003
USA
CL
1
(detail)
124
(54%)
N
71.7 + 8.5
(-)
80.9 + 7.6
(64-98)
97
(53%)
84 + 8.6
(65-101)
Negative
Sherbatykh, 2001
Same as Farrer, 2000 (Russian)
CL
1
(detail)
-
-
-
-
-
-
n.a.
Shulman, 2010
USA
CO
1
(detail)
173
(-)
C
-
-
131
(-)
-
Negative
Sleegers, 2005
Netherlands
PO
1
(detail)
250
(71%)
U
-
82 + 7.3
(-)
6153
(-)
-
Trend
Thornton-Wells, 2008
Re-analysis of Edwards, 2009
CL
0
451
(-)
M
-
-
699
(-)
-
n.a.
Trebunova, 2008
Slovakia
CL
1
(detail)
70
(56%)
C
-
73 + 12
(-)
126
(50%)
72 + 14
(-)
Negative
Webster, 2010
Overlaps with
Corneveaux, 2010
CL
1
(detail)
861
(-)
M
-
82.8 + 7.7
(-)
550
(-)
79.7 + 6.3
(-)
n.a.
Webster, 2010
Germany
CL
1
(detail)
200
(73%)
C
73 + 7.1
(-)
76 + 6.5
(-)
126
(51%)
73 + 6.4
(-)
Positive
Wehr, 2006
Poland
CL
1
(detail)
100
(66%)
C
-
71.8 + 7.9
(52-91)
144
(53%)
70.5 + 8.8
(47-93)
Negative
Zuiliani, 2001
Italy
CL
1
(detail)
40
(70%)
C
-
79.2 + 1
(-)
54
(67%)
82.1 + 0.8
(-)
Negative
Asian
Cheng, 2002
China
CL
1
(detail)
173
(44%)
C
-
74.3 + 6.4
(-)
285
(49%)
53.9 + 8.2
(-)
Positive
Hu, 1999
Japan
CL
1
(detail)
132
(-)
C
-
73.7 + 11
(-)
257
(-)
58.4 + 22
(-)
Positive
Ning, 2010
China
CL
3
(detail)
144
(58%)
C
-
71.6 + 7.3
(-)
476
(64%)
69.3 + 8.7
(-)
Positive
Wakutani, 2002
Japan
CL
1
(detail)
241
(-)
U
-
-
352
(-)
-
Negative
Wang, 2006
Taiwan
CL
2
(detail)
151
(59%)
C
-
74.8 + 7.9
(-)
161
(47%)
62.5 + 8.7
(-)
Positive
Wang, 2007
China
CL
1
(detail)
104
(46%)
C
-
79.2 + 6.3
(64-97)
128
(30%)
68.1 + 2.8
(65-77)
Positive
Wang, 2010
China (XWH)
CL
11
(detail)
237
(57%)
C
69 + 8.9
(-)
72.6 + 8.9
(-)
234
(60%)
71.9 + 8.4
(-)
Negative
Yang, 2000
Overlaps with
Ning, 2010
CL
1
(detail)
188
(60%)
C
70
(-)
74.6 + 8.9
(-)
227
(49%)
74.2 + 8.3
(-)
n.a.
Zhang, 2005
China
CL,PO
1
(detail)
192
(51%)
C
68.9 + 9.3
(45-92)
-
195
(45%)
70 + 7.8
(48-90)
Trend
Hispanic
Camelo, 2004
Colombia
CL
1
(detail)
83
(72%)
C
68.3 + 5
(-)
69 + 8.9
(-)
69
(72%)
71.4 + 12.3
(-)
Negative
Other/Mixed
Bowirrat, 2005
Overlaps with
Meng, 2006
CO
1
(detail)
85
(-)
C
-
-
112
(-)
-
n.a.
Crawford, 2000
USA
CL,CO
1
(detail)
171
(58%)
C
-
-
175
(66%)
-
Positive
Keikhaee, 2006
Iran
CL
1
(detail)
117
(52%)
C
-
73.6 + 6.3
(-)
125
(59%)
69.8 + 6.2
(-)
Negative
Meng, 2006
Israel
CO
12
(detail)
92
(180%)
C
-
-
166
(-)
-
Positive
Perry, 2001
USA
CL
1
(detail)
111
(69%)
M
70.8 + 7.8
(-)
71.3 + 7.7
(-)
78
(76%)
75.2 + 7.6
(-)
Negative
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
Affecteds
Unaffecteds
Study
Population
# Polys
# Families
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Edwards, 2009
USA (CAP, NIMH, IU)
8
(detail)
738
-
M
72.3 + 9.1
(-)
74.8 + 11
(-)
-
-
Positive
Thornton-Wells, 2008
Re-analysis of Edwards, 2009
0
654
1422
(-)
M
-
-
744
(-)
-
n.a.
Other/Mixed
Schjeide, 2009
USA (CAG)
3
(detail)
217
222
(59%)
M
69.2 + 9
(50-89)
-
267
(63%)
72.9 + 8.8
(49-92)
Negative
Schjeide, 2009
USA (NCRAD)
3
(detail)
340
741
(74%)
M
71.3 + 7.6
(50-98)
-
300
(55%)
71 + 8.4
(39-93)
Negative
Schjeide, 2009
USA (NIA)
3
(detail)
351
803
(64%)
M
74.1 + 7.1
(52-98)
-
290
(59%)
73.3 + 9.5
(36-94)
Negative
Schjeide, 2009
USA (NIMH)
3
(detail)
436
995
(74%)
M
72.4 + 7.7
(50-97)
-
411
(58%)
70 + 10.7
(31-93)
Positive
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:
Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:
Number of polymorphisms tested per gene and per sample.
Onset Age and Age:
Mean or median age at onset or examination, respectively.
DX:
Criteria used to determine AD diagnosis -> "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:
Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-)
: Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
APOE
PICALM
MS4A6A
MS4A4A
MS4A4E
EPHA1
CR1
CLU
CD33
CD2AP
BIN1
ABCA7
ARID5B
CELF2
APOC4
BCAM
CLPTM1
PVRL2
LOC3884...
TNK1
MYH13
TOMM40
PCK1
SORL1
LMNA
PGBD1
UBD
GWA_7p1...
GAB2
GOLM1
GWA_15q...
GWA_9p2...
MTHFD1L
LRAT
FAM113B
PCDH11X
GWA_14q...
ATXN1
ADAM10
CD36
DPYS
TGM4
HMMR
LAMB1
PPP3CB
ADORA2B
MTP18
ESR1
CYP19A1
LIPA
CH25H
IL1RN
LPA
MTR
FAS
CHAT
CHRNA2
CHRNA6
CHRNA7
HTR2A
PIN1
NTRK2
SERPINA...
DLST
MAPT/ST...
APOC1
LRRTM3
REN
TNFRSF1...
PIK3R1
FYN
PPP1R3A
NDUFA8
MAPK8IP...
GRIN2B
TNFRSF1...
NDUFA6
PTGS2
HFE
ABCA1
LRP8
PPARG
APBB2
LDLR
IL10
BDNF
PPARA
SOAT1
NOS3
CHRNB2
CETP
MARCH5
ACE
PON1
PON2
CDK5
CTSD
VR22
LRP1
IL6
BACE1
BACE2
PSEN2
PLAU
GSTO1
GSTO2
PRSS11
IDE
CST3
PRNP
NCSTN
TF
MME
PSEN1
TCF7L2
DYRK1A
SORCS2
SORCS3
F11R
TUBB
GRN
NEDD9
ARMS2
SMAD3
VCP
WWC1
DNM2
EBF3
EIF2AK2
SEC24C
SGPL1
ABCG1
LSS
ABCG4
CYP39A1
NCAPD2
GAPDHS
ACTA2
KCNMA1
MYST4
SCD
ANK3
GOT1
SORCS1
TAP2
ENTPD7
DNMBP
CXCL10
VPS26A
C12orf4...
CCNT1
DAPK1
POMT1
IREB2
HMGCR
IGF1R
ABCB1
DSC1
NQO1
HMOX1
LIPC
HMGCS1
RFTN1
APOA1BP
FDPS
HMGCS2
PRKAB2
ADAM12
DHCR24
SOS2
ABCC9
GRB14
HK1
IRS1
NEUROD1
PDE3B
PPARGC1...
PPP1CC
SLC2A2
HECTD2
PITRM1
TARDBP
CDKN2A
IGF1
CSK
CBLC
CARD8
HMOX2
TRPC4AP
GSTZ1
NUMB
POMT2
TMEM63C
THRA
TACR2
OLIG2
TTR
TNMD
EFNA5
MAGI2
CAND1
PPIL2
CDKN2BA...
PTPLA
ACAT2
CHRNB4
DGKB
GWA_10q...
GWA_18q...
GWA_3q2...
HPCAL1
EXOC3L2
GWA_3p2...
ZNF292
PATHWAY...
PATHWAY...
PATHWAY...
TP63
TMEM132...
RGS6
NXPH1
NCAM2
GLOD4
EPHA4
EPC2
CCDC134
ATP6V0A...
ARL5B
AGPAT1
AlzGene Top Results
Top Results Details
1.
APOE_e2/3/4
2.
BIN1
3.
CLU
4.
ABCA7
5.
CR1
6.
PICALM
7.
MS4A6A
8.
CD33
9.
MS4A4E
10.
CD2AP
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Proud supporter of the AlzGene database.
The PDGene database
is supported by a grant from
The Michael J. Fox Foundation
in partnership with the
Alzheimer Research Forum
.
NCRAD
The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.